logo-loader

Full interview: Polarean Imaging begins enrolment for phase III clinical trial at third US site

Published: 00:27 07 Aug 2019 AEST

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site.

The company’s drug-device combination uses hyperpolarised 129-Xenon gas to make magnetic resonance imaging (MRI) more effective in assessing lung function.

Polarean Imaging PLC begins first day of trading on AIM

Polarean Imaging PLC (LON:POLX) chief executive Richard Hullihen dropped into the Proactive studio as the medtech firm kicked off its first day of trading on AIM. The company raised gross proceeds of £3mln via the placing of 20mln ordinary shares at a price of 15p - representing 27.3% of...

on 30/3/18